Description
The p.R191Q pathogenic mutation (also known as c.572G>A), located in coding exon 5 of the GCK gene, results from a G to A substitution at nucleotide position 572. The arginine at codon 191 is replaced by glutamine, an amino acid with highly similar properties. This alteration has been described in the heterozygous state in several unrelated individuals with maturity-onset diabetes of the young (MODY), type 2 (Caetano LA et al. Arq Bras Endocrinol Metabol, 2012 Nov;56:519-24; Pruhova S et al. Pediatr Diabetes, 2010 Dec;11:529-35; Codner E et al. Pediatr Diabetes, 2009 Sep;10:382-8; Codner E et al. Diabetes Metab Res Rev;22:348-55; Fulcoli FG et al. Nat Commun, 2016 06;7:11688; Aykut A et al. Gene, 2018 Jan;641:186-189; Yorifuji T et al. Pediatr Diabetes, 2018 11;19:1164-1172; Massa O et al. Diabetologia, 2001 Jul;44:898-905; Li X et al. BMC Pediatr, 2018 03;18:101; Al-Kandari H et al. Sci Rep, 2021 08;11:16060). This missense alteration is located in a region that has a low rate of benign missense variation (Lek M et al. Nature. 2016 Aug 18;536(7616):285-91; DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources. Firth H.V. et al. 2009. Am.J.Hum.Genet. 84, 524-533 (DOI: dx.doi.org/10/1016/j.ajhg.2009.03.010)). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this variant is expected to be causative of maturity-onset diabetes of the young (MODY), type 2 and permanent neonatal diabetes; however, its clinical significance for GCK-related neonatal hyperinsulinemic hypoglycemia is unclear.
# | Sample | Method | Observation |
---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences |
---|
1 | germline | unknown | not provided | not provided | not provided | | not provided | not provided | not provided | not provided |